TVTX vs. KALV, ALT, OCS, STTK, VERV, LRMR, ANL, CMPS, ABUS, and ATXS
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include KalVista Pharmaceuticals (KALV), Altimmune (ALT), Oculis (OCS), Shattuck Labs (STTK), Verve Therapeutics (VERV), Larimar Therapeutics (LRMR), Adlai Nortye (ANL), COMPASS Pathways (CMPS), Arbutus Biopharma (ABUS), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
KalVista Pharmaceuticals (NASDAQ:KALV) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
KalVista Pharmaceuticals has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
KalVista Pharmaceuticals presently has a consensus target price of $25.00, suggesting a potential upside of 107.30%. Travere Therapeutics has a consensus target price of $16.69, suggesting a potential upside of 144.76%. Given KalVista Pharmaceuticals' higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than KalVista Pharmaceuticals.
KalVista Pharmaceuticals received 276 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
KalVista Pharmaceuticals has a net margin of 0.00% compared to KalVista Pharmaceuticals' net margin of -56.02%. Travere Therapeutics' return on equity of -86.06% beat KalVista Pharmaceuticals' return on equity.
KalVista Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
In the previous week, Travere Therapeutics had 17 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 22 mentions for Travere Therapeutics and 5 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.19 beat Travere Therapeutics' score of 0.02 indicating that Travere Therapeutics is being referred to more favorably in the news media.
Summary
KalVista Pharmaceuticals beats Travere Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
